Study: Diabetes Remission Boosted by Combined Therapy

Diabetes is a chronic metabolic disorder where the body either can’t produce enough insulin (Type 1) or can’t effectively use the insulin it produces (Type 2).

Type 2 diabetes has become a global health crisis for several interconnected reasons. First, it’s strongly linked to lifestyle factors that have become increasingly common worldwide – particularly sedentary behavior, poor dietary habits (especially high consumption of processed foods and sugary drinks), and obesity. The rapid urbanization and economic development in many countries has led to these lifestyle changes. Second, it creates a massive economic burden on healthcare systems due to its chronic nature and expensive complications. Third, it often develops gradually with subtle symptoms, meaning many people have it for years before diagnosis, allowing complications to develop. Fourth, there’s a concerning trend of Type 2 diabetes appearing in younger populations, including children, whereas historically it was mainly seen in older adults. Finally, there’s a strong socioeconomic component – while it affects all populations, it disproportionately impacts lower-income communities who may have limited access to healthy food options, healthcare, and preventive education.

A new study conducted across multiple centers in China has explored the benefits of combining an SGLT-2 inhibitor, dapagliflozin, with calorie restriction for people living with type 2 diabetes (T2D) and obesity. The study focused on participants aged 20–70 with recently diagnosed T2D, a body mass index (BMI) above 25, and blood sugar levels in a specific range. Individuals with significant medical conditions, prior weight-loss surgery, or recent use of weight-loss medications were excluded. Participants were randomly divided into two groups—one receiving dapagliflozin and the other a placebo.

To read more, open the link below: